Neuroimaging methods applied in Parkinson's disease

Journal of Neurology, Supplement

Volumn 251, Issue 6, 2004, Pages

  Leenders, Klaus L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Dopamine; Parkinson's disease; PET; SPECT

Indexed keywords

TECHNETIUM 99M; TRACER;

BRAIN DISEASE; CONFERENCE PAPER; DOPAMINERGIC SYSTEM; HUMAN; ISOTOPE LABELING; NERVE DEGENERATION; NEUROIMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BRAIN; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; DOPAMINE; HUMANS; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 5644275247     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-004-1603-9     Document Type: Conference Paper

References (15)

1. Antonini A, Leenders KL, Vontobel P, Maguire RP, Missimer J, Psylla M, Gunther I (1997) Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 120(Pt 12):2187-2195
2. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 62(2):133-140
3. Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, Sych Z (2003) Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 13(5):259-263
4. 18F]fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods. J Cereb Blood Flow Metab 13(1):57-69
5. Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, Baldwin RM, Zea-Ponce Y, Zoghbi S, Wang S, et al. (1993) Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA 90(24):11965-11969
6. Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Neumeyer J, Margouleff C, Babchyck B, Zanzi I, Eidelberg D (1996) Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/ PET. J Nucl Med 37(11):1760-1765
7. Leenders KL, Palmer AJ, Quinn N, Clark JC, Firnau G, Garnett ES, Nahmias C, Jones T, Marsden CD (1986) Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 49(8):853-860
8. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, Jones T, Marsden CD, Frackowiak RS (1990) The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 47(12):1290-1298
9. 123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57(11):2089-2094
10. Marek K, Jennings D, Seibyl J (2002) Do dopamine agonists or levodopa modify Parkinson's disease progression? Eur J Neurol 9(Suppl 3):15-22
11. 3H]-dopa in rats. Biochem Pharmacol 39(12):1853-1860
12. 18F]CFT PET study. J Cereb Blood Flow Metab 20(11):1604-1609
13. 18F]fluoro-L-dopa PET study. Mov Disord 16(4):608-615
14. Sorenson JA, Phelps ME (1987) Physics in Nuclear Medicine. Philadelphia: WB Saunders Company
15. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ; REAL-PET Study Group (2003) Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 54(1):93-101